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Abstract
Alström Syndrome is an autosomal recessive disease characterized by multiple organ involvement, 
including neurosensory vision and hearing loss, childhood obesity, diabetes mellitus, 
cardiomyopathy, hypogonadism, and pulmonary, hepatic, renal failure, and systemic fibrosis. 
Alström Syndrome is caused by mutations in ALMS1, and ALMS1 protein is thought to play a 
role in microtubule organization, intraflagellar transport, endosome recycling and cell cycle 
regulation. Here, we report extensive phenotypic and genetic analysis of a large cohort of Turkish 
patients with Alström Syndrome. We evaluated 61 Turkish patients, including 11 previously 
reported, for both clinical spectrum and mutations in ALMS1. To reveal the molecular diagnosis of 
the patients, there different approaches were used in combination, a cohort of patients were 
screened by the gene array to detect the common mutations in ALMS1 gene, then in patients 
having any of common ALMS1 mutations were subjected to direct DNA sequencing or next 
generation sequencing for the screening of mutations in all coding regions of the gene. In total, 20 
distinct disease-causing nucleotide changes in ALMS1 have been identified, 8 of which are novel, 
thereby increasing the reported ALMS1 mutations by 6% (8/120). Five disease-causing variants 
were identified in more than one kindred, but most alleles were unique to each single patient and 
identified only once (16/20). So far, 16 mutations identified were specific to the Turkish 
population, and four have also been reported in other ethnicities. Additionally, 49 variants of 
uncertain pathogenicity were noted, and four of these were very rare and probably or likely 
deleterious according to in silico mutation prediction analyses. Alström Syndrome has a relatively 
high incidence in Turkey and the present study shows that the ALMS1 mutations are largely 
heterogeneous; thus, these data from a particular population may provide a unique source for the 
identification of additional mutations underlying Alström Syndrome and contribute to genotype-
phenotype correlation studies.
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INTRODUCTION
Alström Syndrome (ALMS, MIM# 203800) is a recessively inherited genetic disorder 
caused by mutations in ALMS11,2. ALMS is characterized by a complex, progressive, and 
variable clinical expression affecting nearly all organ systems.
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Clinical signs typical in early childhood are cone-rod retinal dystrophy leading to blindness, 
sensorineural hearing loss (SNHL), metabolic abnormalities, and obesity. Dilated mitogenic 
cardiomyopathy (MCM) occurs in approximately 70% of patients peri-natally3,4, and 
ALMS1 mutations are a significant cause of idiopathic MCM5. In addition, restrictive 
cardiomyopathy with fibrosis and pulmonary hypertension can develop during adolescence 
or adulthood3,4. Truncal obesity is a consistent feature, usually beginning in the first 6–18 
months. The obesity increases during childhood but generally tends to moderate as the 
patient grows older. Insulin resistance and diabetes mellitus (DM) are observed in nearly all 
patients before the age of 20 years (y). Hepatic involvement begins with elevated 
transaminases and varying degrees of steatosis and inflammation. In a subset of patients, the 
disease progresses to overt cirrhosis and eventual hepatic failure. Additional presentations 
can include early developmental delay and learning difficulties, hypertension, 
hypertriglyceridemia, chronic otitis media, gastrointestinal reflux disease (GERD), short 
stature, scoliosis, and pes planus. Male hypogonadism is common and females often present 
with hirsutism and menstrual irregularities. Kidney dysfunction begins slowly and is usually 
not seen before the age of 10 y. Increasing systemic fibrosis develops as patients age with 
clinical manifestations of multiple organ failure, including congestive heart failure (CHF), 
hepatic, and end-stage renal disease (ESRD), all of which are frequent causes of morbidity 
and mortality in patients4.
Differential diagnosis of Alström Syndrome can be challenging because of the gradual 
emergence of most of the cardinal features as well as some early clinical similarities to other 
genetic diseases, such as Leber Congenital Amaurosis (LCA), idiopathic cardiomyopathy, or 
Bardet-Biedl Syndrome (BBS)6.
Alström Syndrome is caused by disruptions in ALMS1, which comprises 225 kb of genomic 
DNA, spanning 23 exons and encoding a predicted 461.2 kDa protein1,2. ALMS1 is 
ubiquitously expressed in tissues that are pathologically affected in patients with Alström 
Syndrome7. ALMS1 localizes to centrosomes and to basal bodies of ciliated cells, 
suggesting roles in centrosomal, intracellular and ciliary functions, and regulation of cell 
cycle, and other isoform-specific cellular functions have been shown8,9,10,11.
To date, 120 unambiguous disease-causing mutations in ALMS1 have been reported in 
patients with Alström Syndrome. The majority of disease-causing alleles are nonsense and 
frameshift which would lead to premature protein truncation and are predicted to undergo 
nonsense mediated decay of the corresponding mRNA12,13,14. Exons 16, 10 and 8 account 
for 94% of the mutational load in families of European descent, with the remainder of the 
gene containing rare variants comprising 6%. Chromosomal translocations with a break 
point in ALMS1, AluYa5 elements inserted in ALMS1, and large deletions have also been 
reported in few patients2,15,16.
Our study provides a detailed description of the phenotypes of 61 patients from 44 Turkish 
kindreds. Disease-associated mutations, eight of which are novel, were identified in 41 of 
those for whom genomic DNA material was available.
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METHODS
Sixty seven patients of Turkish descent from 50 kindreds, (33 males and 34 females) with a 
mean age of 15.3 y years (range 3 weeks to 38) were initially identified for the study. They 
were clinically diagnosed with Alström Syndrome through local hospitals and pediatric 
clinics throughout Turkey and Eastern and Western Europe. Alström Syndrome was 
diagnosed on the basis of the established age-dependent diagnostic criteria which require the 
presence of additional cardinal features as the patient grows older and additional 
manifestations develop5. Medical records and clinical questionnaires were investigated 
irrespective of whether genetic analyses were available and included weight, height, cardiac, 
renal, hepatic, endocrine function, and developmental issues. In order to compare all known 
Turkish patients with Alström Syndrome, we included eleven previously reported patients in 
this study. Two patients were excluded after subsequently receiving molecular diagnoses of 
BBS1 and BBS2, respectively. We excluded seven additional subjects (3 male, 4 female) 
based upon an inappropriate phenotype, leaving a total of 50 patients for whom clinical data 
was collected and 11 case reports reviewed.
Patient data was collected from 2000 to 2013. When possible, patients and families were 
followed longitudinally and data updated more than once during the course of the study. 
Because patients were evaluated at several different medical institutions, consistent clinical 
evaluations were not performed in a subset of patients.
Body mass index (BMI) was calculated using the following formula: Weight (in kilograms)/
Height (in meters)2, kg/m2. The Centers for Disease Control and Prevention (CDC) Body 
Mass Index-for-age tables were used to define BMI centiles for age (http://www.cdc.gov/
growthcharts/html_charts/bmiagerev.htm). For children age 2–20 years, weight status 
category for age and gender was determined by these criteria: U:Underweight (BMI <5%); 
N:Normal weight (BMI 5–85%): O=Overweight = BMI 85–95%; OB: Obese = BMI >95%. 
For adults over 20 years BMI was interpreted using standard weight status categories that 
are the same for both men and women: Underweight, BMI<18.5; Normal, BMI18.5–24.9; 
Overweight, BMI 25–29.9; Obese BMI >30; Twenty five patients were previously 
reported16–32. Appropriate informed consent was obtained from all participants. Protocols 
were reviewed and approved by The Jackson Laboratory Institutional Review Board.
Mutation screening strategy
DNA, extracted from venous lymphocytes using standard protocols, was available from 30 
kindreds with a presumed diagnosis of Alström Syndrome. We used the following algorithm 
for genetic diagnosis (Figure 1).
One subset of 16 kindreds was analyzed on an Arrayed Primer Extension (APEX) 
microarray to identify known ALMS1 mutations (Asper Ophthalmics; 
www.asperophthalmics.com)14. The test array contained 113 ALMS1 genetic variants, as 
well as BBS gene mutations BBS1, BBS2, BBS3, BBS4, BBS5, BBS6, BBS7, BBS8, 
BBS10, PHF6 (Borjeson-Forssman-Lehman syndrome), and GNAS1 (Albright hereditary 
osteodystrophy), including polymorphisms and variants of uncertain pathogenicity. (See 
Supplementary Table S1 for positions screened on the Asper Ophthalmics Array).
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A second subset of DNA from 14 kindreds was directly Sanger sequenced, likewise focusing 
on exons 16, 10 and 8 first. When both ALMS1 mutations were identified in these exons, the 
sequencing was stopped. If only one mutant allele found or none in exon 16, 10, 8, all exons 
were subjected to Sanger sequencing. After sequencing, the eight kindreds for whom no 
mutated alleles were identified were simultaneously sequenced with the Targeted Gene 
Sequencing and Custom Analysis (TaGSCAN) test33. Briefly, samples were prepared for 
Illumina-based NGS with standard methods, enriched twice by incubation with 20,477 
capture probes targeting 8,366 exons of 514 genes that correspond to 764 childhood genetic 
diseases.
Primers were designed for polymerase chain reaction (PCR) amplification of all coding and 
splice-site sequences of ALMS1. PCR reactions and amplification conditions were 
performed as previously described1. Primer sequences are available from the authors upon 
request. Sequences were compared to ALMS1 (GenBank NM_015120.4; AC074008.5) 
using MacVector TM 7.2.3 (MacVector Inc., Cary, NC). Nucleotide and amino acid 
numbering of mutation sites began at the start codon, ATG (Met) of the open reading frame, 
originally described by Collin et al. and Hearn et al1,2.
A mutation was considered novel if it has not been described in the medical literature, or is 
not present in the Human Mutation Database (www.hgmd.cf.ac.uk/ac), the dbSNP database 
(www.ncbi.nlm.nih.gov/projects/SNP/index.html), the Exome Variant Server 
(evs.gs.washington.edu/EVS), or the LOVD database (www.lovd.com).
To assess the pathogenicity of nonsynonymous allelic variations, the bioinformatics 
prediction software programs PolyPhen-2 (Polymorphism Phenotyping v2: http://
genetics.bwh.harvard.edu/pph2/dokuwiki/downloads) and Sorting Intolerant From Tolerant 
(SIFT:http://sift.jcvi.org) were used, along with a minor allele frequency (MAF) score from 
the Exome Variant Server, National Heart Lung Blood Institute, Grand Opportunity Exome 
Sequencing Project, 6500 exomes, accessed 5/19/2014) (NHLBI GO ESP; 
evs.gs.washington.edu/). These tools predict possible impact of a nonsynonymous amino 
acid substitution on the structure and function of a protein based on sequence homology, 
conservation of sequences, and the physical properties of amino acids34,35.
RESULTS
Clinical features and identified genotypes of the 61 patients enrolled in this study are 
summarized in Table 1. To our knowledge, 22 kindreds (48%) were born to consanguineous 
marriages, and 23 were either non-consanguineous or the family history was not known. All 
patients were of Turkish origin from different geographical regions of Turkey and Turkish 
immigrants living in Europe.
Clinical findings
Many of the features typical in Alström Syndrome display age-related penetrance. There is 
also a wide spectrum in severity of the disease phenotypes. Ten patients died before age 38 
y, and their average age of death was 17 y.
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Sensory loss—Retinal dystrophy within the first year was a consistent feature in our 
cohort, with the exception of four patients whose vision impairment was not noticed or 
reported until early childhood. Electroretinography was not always available for families 
from isolated locations. We observed hearing loss in 34 of the 47 patients over the age of 4 y, 
with an average age of onset of 7 y.
Obesity—Relatively mild obesity phenotypes are noted in this cohort of patients. We found 
that 14 (5 males, 9 females) out of 61 patients (age range 6–36 years) had normal weight 
(22.5%), and only one was morbidly obese (patient 39 with a BMI of 43.4 kg/m2). The 
average BMI was 27.3 +/−5.9 (N=40).
Diabetes and endocrinological dysfunction—The youngest age of onset of diabetes 
was 6 y (patient 44). Of the 54 cases in our cohort 6 years and older, 6 were 
hyperinsulinemic or glucose intolerant, and 36 (66%) had diabetes. Endocrinological 
abnormalities included hypogonadotropic hypogonadism in males and menstrual 
irregularities and early puberty in females, short stature, advanced bone age, 
hypertriglyceridemia, hypothyroidism, hyperthyroidism, and alopecia.
Although not assessed in all patients, growth hormone deficiency was reported in 6 patients 
(patients 12,52,53,54,57,59).
Cardiopulmonary—Nineteen of the 61 (30%) patients in our cohort have had 
cardiomyopathy. There were two siblings with mitral valve insufficiency (patients17,18), 
one patient of patent foramen ovale (patient 12), and another patient with a systolic murmur 
(patient 59). Although not proven, the death of two young patients (patients 58, 60) could 
likely be attributed to the infantile cardiomyopathy that is common in Alström 
Syndrome3,36.
Hepatic—Liver size and enzymes were increased in 35 of 61 (58%) of patients. These 
patients (patients 13, 22, and 61) had severe cirrhosis and portal hypertension with upper 
gastrointestinal (UGI) bleeding.
Renal dysfunction—Patients age 12 y or older were considered for renal involvement 
(n=41). Fifteen showed functional abnormalities in the renal system, which included 
proteinuria, renal calculi, hyperuricemia, pelviectasis, and microalbuminuria. Two patients 
presented with renal disease earlier than typical in ALMS: One (patient 40) presented with 
chronic renal insufficiency at age 2 months, and another (patient 28) had severe ESRD at age 
5 years, and subsequently died with multiple organ failure.
Neurological findings—Neurological symptoms in 18/61 (29%) patients included mild 
ataxia, hypotonia, poor balance, or febrile and afebrile seizures. Four patients (patients 12, 
13, 26, and 27) had microcepahaly, cortical atrophy, or abnormalities observed in MRI, and 
another (patient 59) had cerebral hemiatrophy.
Psychomotor development and intelligence—Cognitive deficits and motor 
impairment was documented in half of the patients (32/61). These represented a range of 
Ozantürk et al. Page 6
J Hum Genet. Author manuscript; available in PMC 2017 June 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
developmental issues from severe to milder cognitive impairments, gross and fine motor 
delay, language delay, attention deficit disorder (ADD), and autistic spectrum behavior. Of 
those 30 analyzed for genetic mutations, 18 presented with some degree of cognitive 
impairment. Array CGH to detect copy number variations has not been carried out on these 
patient’s DNA samples.
Other clinical manifestations—The results of our study confirm that pulmonary 
dysfunction (16 patients), short stature/scoliosis (16 patients), hypertension (8 patients), and 
urological symptoms (7 patients) are very frequent medical complications in Turkish 
patients with Alström Syndrome.
There were no significant differences in vision, hearing loss, obesity, cardiomyopathy, liver 
and renal function, and developmental delay between patients in whom disease-causing 
mutations were identified and in those who had not received a molecular confirmation.
Mutation screening and DNA sequencing results
In total, 30 kindreds with a phenotypic diagnosis of Alström Syndrome were screened for 
ALMS1 mutations. Of the 16 kindreds analyzed using the Asper Ophthalmics Array, 
homozygous disease-causing mutations were identified in three, and 13 were negative for 
any ALMS1 mutations on the Array. DNA from those 13 negative kindreds was then Sanger 
sequenced, focusing on exons 16, 10 and 8 first, and then if no mutations were found, 
sequencing the remaining exons. In seven kindreds both ALMS1 mutated alleles were 
identified and one heterozygous mutated allele was identified in one kindred. In five 
kindreds from this cohort, we were not able to identify any disease-causing ALMS1 
mutations.
DNA from another cohort of 14 patients was not submitted to the Asper Ophthalmics Array, 
but Sanger sequenced directly. In this cohort of 14, both ALMS1 mutated alleles were 
identified in nine kindreds and one mutated allele identified in two kindreds. Using both 
methods, sixteen of 30 had homozygous ALMS1 mutations and in three, only one 
heterozygous mutation was identified.
In these eight kindreds, exomes were then evaluated by high throughput sequencing, and in 
3 of 8 homozygous ALMS1 mutations were detected.
Therefore, with the three methods combined, 19 kindreds had homozygous mutations, in 3 
kindreds, only one deleterious allele was identified. In 8 of our kindreds, no mutations were 
found.
Eight novel and 12 previously reported12, 16, 23, 27, 28, 31, 37 mutations were identified in 
exons 8, 10, 11, 16 and intron 18 in 25 kindreds (Table 1 and 2).
Ten were nonsense mutations, nine were frameshift mutations, and one intronic splice site 
mutation identified which was previously reported to be pathogenic37.
Five mutations were seen in more than one of apparently unrelated kindreds: c.4156insA; 
p.Thr1386AsnfsX15 (two kindreds), c.5311C>T; p.Gln1769* (two kindreds), c.5969C>G; 
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p.Ser1990* (three kindreds), and c.11870-3T>G (two kindreds). Additionally, we identified 
c.8506G>T; p.Glu2836* in three kindreds from the Konya that were not knowingly related 
to each other (kindred 14, 15, 16), suggesting an early founder effect in that region.
Interestingly, kindred 6, residing in a rural village outside of İnebolu, Kastamonu, is 
comprised of three siblings heterozygous for c.5311C>T; p.Gln1769* in exon 8, and c.
10563_10564delTA; p.His3521Glnfs*16 in exon 16. Their first cousin, also affected, carried 
p.Gln1769* in homozygous state. The remaining mutations were only identified in one 
kindred each, ruling out potential founder effects.
Three kindreds (kindreds 7, 10, 19) harbored three mutated alleles. Patient 10 (kindred 7), 
homozygous for p.Tyr1862*, also carried a third deleterious allele, p.Leu968fs*430. Patient 
13 (kindred 10) was homozygous for a splice site mutation c.11870-3T>G while carrying a 
third ALMS1 stop mutation, p.Ser1990* in exon 8. Finally, as we described previously, 
patient 27 (kindred 19) is homozygous for p.Ser3250* and also carries a heterozygous 
intronic mutation IVS19-8delT27.
An intriguing observation was that in three kindreds (kindred 1,12, 13) only one 
heterozygous mutation was identified, no other potentially deleterious alterations were 
found, despite extensive molecular sequencing of the coding regions. However, 49 variants 
of uncertain pathogenicity were identified in 44 kindreds (31 nonsynonymous, 13 
synonymous, one deletion and 4 intronic nucleotide changes). Nonsynonymous variations 
were evaluated using two different in silico protein prediction programs (PolyPhen-2; and 
SIFT); and their minor allele frequencies are reported in Supplementary Table S2. We 
consider the variations which have less than 1% MAF and were predicted damaging from 
both PolyPhen and SIFT, as most probably deleterious allelic variations.
Based on their rarity and in silico prediction results, four novel variations (p.Asp505Asn, 
p.Ser764Phe, p.Asp3295Tyr, p.Asn3306Ser), might be deleterious and contribute to the 
patients’ phenotype. An amino acid change p.Asp505Asn, predicted to be damaging and not 
seen before in controls, was detected in patient 33 who is also homozygous for 
p.Ile773Phefs*13. Likewise, p.Ser764Phe (MAF %0.008) was identified in patient 12 who 
harbored one deleterious heterozygous mutation, p.Ser1990*. No nonsense or frameshift 
mutations were detected in kindreds 24 and 25. However, two patients from kindred 24 were 
homozygous for a rare variation, p.Asn3306Ser (MAF 0.3%) and patient 36 (kindred 25) 
was homozygous for novel missense variation, p.Asp3295Tyr. These results lend support to 
the notion that these rare allelic variations most probably contribute or drive the disease 
phenotype of the patients in these families. Since the high degree of variation within 
ALMS1, further functional studies will be required to determine the potential pathogenicity 
of these variants.
There were 13 synonymous variants, of which c.2764C>A (rs143885319) was the most 
common, carried by 36% of the families (MAF 49,5% in EVS). A 5’ splice site variant c.
767+20T>A (rs1881246) was also seen in five families, p.Arg4031Lys (rs1320374) whose 
MAF is 46,3%, is the most common nonsynonymous allele in the cohort (Supplementary 
Table S2 shows nonsynonymous and synonymous alterations observed).
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DISCUSSION
In this study, we review clinical phenotypes in a large series of 61 Turkish patients with 
Alström Syndrome. We report eight novel ALMS1 mutations and four additional 
nonsynonymous rare alleles that could be potentially disease-associated variants.
Alström Syndrome has an estimated prevalence of <1:1,000,000 in Europe and North 
America13, with the frequency higher in geographically or culturally isolated populations 
where consanguinity is more common, a well-established phenomenon. However, genetic 
homogeneity and founder effects in this study population clearly cannot be invoked as 
plausible explanations for the high incidence of Alström Syndrome in Turkey, since 20 
different ALMS1 mutations have been identified so far in Turkish patients. This implies that 
Alström Syndrome in Turkey is likely a result of multiple isolates rather than being 
attributable to a single founder. Located between Europe and Asia, Anatolia served as a 
gateway for various ethnicities, which may contribute to form a diverse and a unique genetic 
background. Hence, finding a wide variety of different allelic variations and deleterious 
mutations is not surprising. It is notable that four of the most common ALMS1 mutations in 
the world population13 (10775delC, c.10483delC, 11316_11319delAGAG, and c.
11449C>T), are absent in the Turkish cohort. Conversely, 80% of the variants found in 
Turkish kindred’s have not been seen in other ethnicities, which emphasizes the population 
specificity of some ALMS1 mutations, and has potential diagnostic implications.
Previous reports have shown ‘hot spots’ for deleterious mutations in exon 16 (41%), exon 10 
(27%), and exon 8 (25%).12,13 Although 97% of the pathogenic alleles in this cohort are 
clustered in the ‘hot spots’, in our cohort, there were more than expected in exon 8 (40%) 
and 10 (32%), and fewer than expected (25%) in exon 16 and no missense variants or SNPs 
were detected in these exons in any of our patients.
Consanguinity is reported in only a minority of patients of European origin, but founder 
effects have been suggested in the Acadian population in Nova Scotia38 and in a UK 
cohort12. In the Turkish population, with an estimated population of 81,619,392 
[www.cia.gov, July 2014], the consanguinity rate is estimated to be between 20–25%39 and 
it is not currently feasible to accurately determine the prevalence of Alström Syndrome.
Another possible reason is that the clinical diagnostic criteria of this disorder are not always 
well known to the clinicians. Additionally, the emerging phenotype as the child grows poses 
a diagnostic challenge for pediatricians. Therefore, many affected individuals likely remain 
undiagnosed.
Including this study, there are 120 predicted disease-causing ALMS1 mutations reported to 
date in patients of diverse ethnic and national origins13. The mutation detection rate is 
relatively low, as 5/31 patients whose coding regions were sequenced had no mutations 
identified. It is possible, indeed likely given their clinical presentation that a mutation exists 
in the intronic regions but was not detected. We cannot exclude cryptic splicing mutations, 
which can be very difficult to identify on direct DNA sequencing. Further, the possibility 
that some of the additional missense variants we identified are pathogenic cannot be 
excluded. Finally, allelic variations which may modify or interact with ALMS1 require 
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further investigation. Therefore, future genetic studies of the disease should consider the 
next generation sequencing approach which allows us to see all variations of the genome or 
exome of an individual.
Genotype-phenotype correlation
The ALMS phenotype is highly variable within and between families but, at this time, there 
are few studies presenting any genotype-phenotype correlation. Although variable 
expressivity has been reported widely, the clinical manifestations between our nine sets of 
siblings were very similar. There were seven patients who had both mutated alleles in exon 
8, four patients with both mutations in exon 10, and one patient with both mutations in exon 
11. Although the numbers are small, there were no significant differences in clinical course 
between patients with homozygous mutations in a specific exon and different biallelic 
ALMS1 mutations located in two different exons.
ALMS1 which spans 225 kb is a large and repetitive gene and the mutational load is quite 
high, especially combined with the high prevalence of consanguineous marriages in Turkey. 
Therefore, it is not surprising that we detect more allelic variations in the population. In this 
light, we might explain the patients (patients 10, 13, 29) who harbor three different 
deleterious variations in the ALMS1 gene. However, the phenotypes of the three patients did 
not differ from the other patients for whom one or two alleles were found. Furthermore, their 
presence did not correlate with increasing disease severity as estimated by the number of 
primary or secondary features of the disease. Therefore, it is hard to predict the effect of the 
third allele on the protein without functionally testing the alleles together. As DNA samples 
of parents were not available, we could not show segregation of the variations within the 
family.
Although most of the phenotypic manifestations that are present in our cohort did not differ 
from the classical features, we want to emphasize that the characteristics of pulmonary 
dysfunction, urological dysfunction, and neurological abnormalities are frequent in this 
group of patients.
This is the first comprehensive study of Alström Syndrome in Turkey. We estimate that 
Alström Syndrome is under-reported in this population. Most patients with Alström 
Syndrome manifest classic features that could lead to a diagnosis in early childhood. 
Although a great effort was made to identify and include all known patients in Turkey, it is 
likely that many individuals with Alström Syndrome remain unidentified. Many families 
have limited contact with the health care system, and single sporadic patients are often 
missed. Earlier and more accurate clinical diagnosis will improve patient care and 
monitoring, and will present an opportunity to uncover novel disease-causing mutations in 
ALMS1.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Mutation screening algorithm for genetic diagnosis of patients for ALMS1 gene
Three different approaches were used for mutation detection; a cohort of patients were 
screened by the gene array to detect the common mutations in ALMS1 gene, then in patients 
with any of this common ALMS1 mutations were subjected to direct DNA sequencing or 
next generation sequencing
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